Document 0842
 DOCN  M9470842
 TI    High-dose fluconazole for treatment of cryptococcal disease in patients
       with human immunodeficiency virus infection. The California
       Collaborative Treatment Group.
 DT    9409
 AU    Haubrich RH; Haghighat D; Bozzette SA; Tilles J; McCutchan JA;
       Department of Medicine, University of California, San Diego; 92103.
 SO    J Infect Dis. 1994 Jul;170(1):238-42. Unique Identifier : AIDSLINE
       MED/94284648
 AB    Eight patients (6, cryptococcal meningitis; 2, high-titer cryptococcal
       antigenemia) were treated with 800 mg/day fluconazole to assess the
       safety and efficacy of high-dose fluconazole as primary therapy. Five
       patients with meningitis had resolution of clinical symptoms and all 6
       had negative cerebrospinal fluid (CSF) cultures by day 82 (median, 21
       days). One meningitis patient developed neurologic deterioration and was
       switched to amphotericin B at day 18, but CSF culture was negative on
       day 15 of fluconazole therapy. In 2 patients with cryptococcal
       antigenemia, clinical symptoms resolved and serum antigen titers
       declined rapidly; they did not progress to meningitis. Therapy was well
       tolerated, with mainly gastrointestinal side effects. Four patients had
       mild increases in liver enzymes; another had a threefold increase in
       alkaline phosphatase. Mean steady-state serum level of fluconazole was
       45 +/- 15 micrograms/mL, and paired CSF and serum levels were 40 +/- 14
       and 49 +/- 14 micrograms/mL, respectively. High-dose fluconazole appears
       safe and effective for cryptococcal disease in AIDS patients.
 DE    AIDS-Related Opportunistic Infections/*DRUG THERAPY
       Cryptococcosis/COMPLICATIONS/*DRUG THERAPY  Fluconazole/ADMINISTRATION &
       DOSAGE/*THERAPEUTIC USE  Human  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).